Skip to content
OmniAb
  • About
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antibody Generation
      • Antigen Design
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmnidAb
      • OmniTaur
      • Bispecific Platforms
    • xPloration Screening
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • In Silico Technologies
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Financials
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Environment
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antibody Generation
      • Antigen Design
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmnidAb
      • OmniTaur
      • Bispecific Platforms
    • xPloration Screening
    • Antibody Optimization
      • Fc-Silencing Technology
    • Ion Channel and Transporter Technology
    • In Silico Technologies
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Financials
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Environment
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

Partner Pipeline

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development
partner
program
source
area
phase 1
phase 2
phase 3
registration
approved
Gloria Pharmaceuticals
Arcus Biosciences
Gilead

Zimberelimab

OmniRat Oncology
CStone Pharmaceuticals
Pfizer

Sugemalimab

OmniRat Oncology
J&J Innovative Medicine

Teclistamab

OmniRat Oncology
Hanall Biopharma
Immunovant
Harbour BioMed

Batoclimab

OmniRat Immunology
Genmab

Acasunlimab

OmniRat Oncology
SalubrisBio

SAL003

OmniRat Metabolic
Genentech

Tiragolumab

OmniRat Oncology
AbbVie

ABBV-383

OmniFlic Oncology
AstraZeneca

AZD0486

OmniFlic Oncology
Merck KGaA

M6223

OmniRat Oncology
Teva

TEV-53408

OmniRat Gastrointestinal
Hanall Biopharma
Immunovant

IMVT-1402

OmniRat Immunology
J&J Innovative Medicine

JNJ-70218902

OmniRat Oncology
Aptevo Therapeutics

APVO436

OmniMouse Oncology
CTTQ

TQB2223

OmniRat Oncology
Symphogen by Servier

S95018

OmniRat Oncology
Symphogen by Servier

S95024

OmniRat Oncology
Symphogen by Servier

S95029

OmniRat Oncology
Zhilkang Hongyi

Undisclosed

OmniRat Oncology
Curon

CN1

OmniRat Oncology
Boehringer Ingelheim

BI 765179

OmniChicken Undisclosed
Merck KGaA

M9140

OmniRat Oncology
J&J Innovative Medicine

JNJ-79635322

OmniRat Oncology
Pfizer

PF-08046049 (SGN-BB228​)

OmniRat Oncology
Gloria Pharmaceuticals

GLS-012

OmniRat Oncology
Cessation Therapeutics

CSX1004

OmniRat Drug overdose
BioCity

BC3195

OmniRat Oncology
Teva

TEV-56278

OmniChicken Oncology
Genmab

GEN1057

OmniRat Oncology
Merck

M5542

OmniRat Immunology
Innolake Biopharm

ILB2101

OmniRat Oncology
J&J Innovative Medicine

JNJ-87562761

OmniRat Oncology
Genmab

GEN1078

OmniRat Undisclosed
PartnerGloria Pharmaceuticals
Arcus Biosciences
Gilead
Program

Zimberelimab

SourceOmniRat
AreaOncology
PhaseApproved
PartnerCStone Pharmaceuticals
Pfizer
Program

Sugemalimab

SourceOmniRat
AreaOncology
PhaseApproved
PartnerJ&J Innovative Medicine
Program

Teclistamab

SourceOmniRat
AreaOncology
PhaseApproved
PartnerHanall Biopharma
Immunovant
Harbour BioMed
Program

Batoclimab

SourceOmniRat
AreaImmunology
PhaseRegistration
PartnerGenmab
Program

Acasunlimab

SourceOmniRat
AreaOncology
PhasePhase 3
PartnerSalubrisBio
Program

SAL003

SourceOmniRat
AreaMetabolic
PhasePhase 3
PartnerGenentech
Program

Tiragolumab

SourceOmniRat
AreaOncology
PhasePhase 3
PartnerAbbVie
Program

ABBV-383

SourceOmniFlic
AreaOncology
PhasePhase 3
PartnerAstraZeneca
Program

AZD0486

SourceOmniFlic
AreaOncology
PhasePhase 3
PartnerMerck KGaA
Program

M6223

SourceOmniRat
AreaOncology
PhasePhase 2
PartnerTeva
Program

TEV-53408

SourceOmniRat
AreaGastrointestinal
PhasePhase 2
PartnerHanall Biopharma
Immunovant
Program

IMVT-1402

SourceOmniRat
AreaImmunology
PhasePhase 2
PartnerJ&J Innovative Medicine
Program

JNJ-70218902

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerAptevo Therapeutics
Program

APVO436

SourceOmniMouse
AreaOncology
PhasePhase 1
PartnerCTTQ
Program

TQB2223

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerSymphogen by Servier
Program

S95018

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerSymphogen by Servier
Program

S95024

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerSymphogen by Servier
Program

S95029

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerZhilkang Hongyi
Program

Undisclosed

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerCuron
Program

CN1

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerBoehringer Ingelheim
Program

BI 765179

SourceOmniChicken
AreaUndisclosed
PhasePhase 1
PartnerMerck KGaA
Program

M9140

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerJ&J Innovative Medicine
Program

JNJ-79635322

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerPfizer
Program

PF-08046049 (SGN-BB228​)

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerGloria Pharmaceuticals
Program

GLS-012

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerCessation Therapeutics
Program

CSX1004

SourceOmniRat
AreaDrug overdose
PhasePhase 1
PartnerBioCity
Program

BC3195

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerTeva
Program

TEV-56278

SourceOmniChicken
AreaOncology
PhasePhase 1
PartnerGenmab
Program

GEN1057

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerMerck
Program

M5542

SourceOmniRat
AreaImmunology
PhasePhase 1
PartnerInnolake Biopharm
Program

ILB2101

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerJ&J Innovative Medicine
Program

JNJ-87562761

SourceOmniRat
AreaOncology
PhasePhase 1
PartnerGenmab
Program

GEN1078

SourceOmniRat
AreaUndisclosed
PhasePhase 1


Program placement is based on most advanced status

Italicized programs do not have future or remaining economics to OmniAb

About

  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

Contact | Privacy Policy | Disclaimer

© 2025 OmniAb, Inc. All rights reserved.